[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kodiak Sciences Inc (KOD)

Kodiak Sciences Inc (KOD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,557,563
  • Shares Outstanding, K 62,578
  • Annual Sales, $ 0 K
  • Annual Income, $ -229,970 K
  • EBIT $ -235 M
  • EBITDA $ -209 M
  • 60-Month Beta 2.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 23.64

Options Overview Details

View History
  • Implied Volatility 103.91% (-10.76%)
  • Historical Volatility 61.51%
  • IV Percentile 32%
  • IV Rank 40.34%
  • IV High 165.59% on 08/01/25
  • IV Low 62.19% on 09/08/25
  • Expected Move (DTE 31) 8.23 (19.00%)
  • Put/Call Vol Ratio 2.73
  • Today's Volume 164
  • Volume Avg (30-Day) 517
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 18,703
  • Open Int (30-Day) 16,722
  • Expected Range 35.07 to 51.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.97
  • Number of Estimates 3
  • High Estimate $-0.95
  • Low Estimate $-0.99
  • Prior Year $-1.03
  • Growth Rate Est. (year over year) +5.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.46 +28.60%
on 06/25/26
44.85 -4.06%
on 07/20/26
+6.89 (+19.06%)
since 06/18/26
3-Month
29.21 +47.31%
on 06/09/26
47.84 -10.06%
on 04/22/26
-3.11 (-6.74%)
since 04/21/26
52-Week
5.00 +760.58%
on 07/22/25
47.84 -10.06%
on 04/22/26
+37.95 (+747.05%)
since 07/21/25

Most Recent Stories

More News
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference

PALO ALTO, Calif. , May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing...

KOD : 43.19 (+5.68%)
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

PALO ALTO, Calif. , May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.

KOD : 43.19 (+5.68%)
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

PALO ALTO, Calif. , May 1, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing...

KOD : 43.19 (+5.68%)
Kodiak Sciences: When Clinical Progress Stops Excusing the Cash Burn Rate

Barchart Research What to Expect from KOD Earnings KOD Generated April 1, 2026 Current Price $42.81 EPS Estimate $$-0.86 Consensus Rating Moderate Buy Average Move 7.69% Kodiak Sciences: When Clinical...

KOD : 43.19 (+5.68%)
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

PALO ALTO, Calif. , March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31,...

KOD : 43.19 (+5.68%)
Stocks Slump on Iran War and Weakness in Chipmakers

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -1.74%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.01%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.38%. June...

AMAT : 565.10 (+7.49%)
GOOGL : 348.87 (-0.89%)
MPC : 318.42 (+0.99%)
AAPL : 327.69 (+0.34%)
B : 36.24 (+3.87%)
AVGO : 386.26 (+2.14%)
SNDK : 1,576.15 (+13.31%)
HL : 15.26 (+6.79%)
CDE : 15.26 (+7.77%)
ADI : 382.79 (+2.77%)
BF.B : 26.27 (-0.53%)
$IUXX : 29,125.42 (+1.82%)
Iran Ceasefire Skepticism Weighs on Stocks

The S&P 500 Index ($SPX ) (SPY ) today is down -0.64%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.16%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.05%. June E-mini S&P futures...

AMAT : 565.10 (+7.49%)
GOOGL : 348.87 (-0.89%)
SNDK : 1,576.15 (+13.31%)
HL : 15.26 (+6.79%)
CDE : 15.26 (+7.77%)
$IUXX : 29,125.42 (+1.82%)
ASML : 1,806.46 (+3.88%)
ZNU26 : 108-210 (-0.19%)
ESU26 : 7,546.50 (+0.83%)
STX : 894.66 (+11.49%)
WDC : 546.90 (+12.20%)
LRCX : 322.74 (+5.21%)
Stocks Fall as Crude Oil Jumps on Doubts About a Ceasefire in Iran

The S&P 500 Index ($SPX ) (SPY ) today is down -0.50%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.77%. June E-mini S&P futures...

AMAT : 565.10 (+7.49%)
B : 36.24 (+3.87%)
AVGO : 386.26 (+2.14%)
SNDK : 1,576.15 (+13.31%)
HL : 15.26 (+6.79%)
CDE : 15.26 (+7.77%)
$IUXX : 29,125.42 (+1.82%)
ASML : 1,806.46 (+3.88%)
ZNU26 : 108-210 (-0.19%)
ESU26 : 7,546.50 (+0.83%)
STX : 894.66 (+11.49%)
WDC : 546.90 (+12.20%)
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkudaâ„¢ (tarcocimab tedromer) Over Sham

PALO ALTO, Calif. , March 26, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing...

KOD : 43.19 (+5.68%)
Kodiak Sciences Faces Critical Test as Losses Mount and Analyst Confidence Wavers

Barchart Research What to Expect from KOD Earnings KOD Generated March 25, 2026 Current Price $22.75 EPS Estimate $-1.02 Consensus Rating Moderate Buy Average Move 7.69% Kodiak Sciences Faces Critical...

KOD : 43.19 (+5.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kodiak Sciences Inc. is a clinical stage biopharmaceutical company engaged in developing novel therapeutics to treat chronic, high-prevalence retinal diseases, which are the major causes of blindness. The company's proprietary antibody biopolymer conjugate (ABC) platform is designed to maintain potent...

See More

Key Turning Points

3rd Resistance Point 47.74
2nd Resistance Point 46.30
1st Resistance Point 43.58
Last Price 43.19
1st Support Level 39.42
2nd Support Level 37.98
3rd Support Level 35.26

See More

52-Week High 47.84
Last Price 43.19
Fibonacci 61.8% 31.48
Fibonacci 50% 26.42
Fibonacci 38.2% 21.37
52-Week Low 5.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.